Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD (SHE:300534)
China flag China · Delayed Price · Currency is CNY
10.22
-1.08 (-9.56%)
Nov 13, 2026, 3:04 PM CST

SHE:300534 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
688.57865.261,0281,067788.26280.05
Other Revenue
21.721.714.8812.8911.427.77
710.26886.961,0431,080799.68287.81
Revenue Growth
-21.34%-14.92%-3.48%35.06%177.85%12.91%
Cost of Revenue
245.57283.41291.37386.79341.62195.48
Gross Profit
464.69603.55751.13693.26458.0692.33
Selling, General & Admin
364.93467.9617.94560.01364.3790.06
Research & Development
22.3427.1528.1330.1727.126.7
Other Operating Expenses
16.7913.5613.2212.344.993.75
Operating Expenses
410.8516.08655.12611.43401.75101.65
Operating Income
53.8987.4796.0281.8256.31-9.31
Interest Expense
-2.5-2.66-3.34-3.95-0.5-0.53
Interest & Investment Income
3.234.747.397.174.32.32
Currency Exchange Gain (Loss)
-0.01-0.01-00.010.02-0.06
Other Non Operating Income (Expenses)
17.580.11-2.0602.1-0.11
EBT Excluding Unusual Items
72.1989.669885.0562.24-7.7
Impairment of Goodwill
------4.78
Gain (Loss) on Sale of Investments
-0-0-0.21---
Gain (Loss) on Sale of Assets
-0.06-0.01-0.69-0.24-0.06
Asset Writedown
-0.48----0.1-
Other Unusual Items
-4.6-8.54.6612.247.67
Pretax Income
67.0581.15101.7697.0266.14-4.75
Income Tax Expense
21.8215.7851.6813.1717.491.55
Earnings From Continuing Operations
45.2365.3650.0883.8548.65-6.3
Minority Interest in Earnings
-20.66-21.41-25.6-22.2-9.87-2.81
Net Income
24.5743.9524.4861.6538.79-9.11
Net Income to Common
24.5743.9524.4861.6538.79-9.11
Net Income Growth
12.59%79.56%-60.30%58.95%--
Shares Outstanding (Basic)
304303303303303304
Shares Outstanding (Diluted)
304303303303303304
Shares Change
0.11%0.01%-0.03%0.05%-0.10%-0.54%
EPS (Basic)
0.080.140.080.200.13-0.03
EPS (Diluted)
0.080.140.080.200.13-0.03
EPS Growth
12.46%79.55%-60.28%58.87%--

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
64.81-49.9137.23-29.83242.0350.72
Free Cash Flow Per Share
0.21-0.170.45-0.100.800.17
Dividend Per Share
0.0200.0400.0400.020--
Dividend Growth
-50.00%0%100.00%---
Gross Margin
65.43%68.05%72.05%64.19%57.28%32.08%
Operating Margin
7.59%9.86%9.21%7.58%7.04%-3.24%
Profit Margin
3.46%4.96%2.35%5.71%4.85%-3.16%
Free Cash Flow Margin
9.12%-5.63%13.16%-2.76%30.27%17.62%
EBITDA
98.01129.18134.51111.7383.313.25
EBITDA Margin
13.80%14.56%12.90%10.34%10.42%4.60%
D&A For EBITDA
44.1241.7138.529.926.9922.56
EBIT
53.8987.4796.0281.8256.31-9.31
EBIT Margin
7.59%9.86%9.21%7.58%7.04%-3.24%
Effective Tax Rate
32.54%19.45%50.78%13.57%26.44%-
Revenue as Reported
710.26886.961,0431,080799.68287.81
Advertising Expenses
-0.690.95---